

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

**INSIDE INFORMATION ANNOUNCEMENT
PROFIT WARNING**

This announcement is made by Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (the “**Year 2025**”) and other information currently available, the Group is expected to record a decrease of approximately 80% to 120% in the profit attributable to the owners of the Company for the Year 2025, as compared to the corresponding period in 2024. The decrease was mainly due to the loss of provision for impairment of goodwill incurred by the Group in the acquisition of Beijing Neptunus Zhongxin Pharmaceutical Co., Limited.

The information in this announcement is only based on the preliminary assessment made by the Board based on the review of the information currently available to the Group, including the unaudited consolidated management accounts of the Group for the Year 2025, and such information has not been audited by the Company’s independent auditors. The Group’s results for the Year 2025 are subject to further audit and review, and have not been finalized. As such, the actual results for the Year 2025 may or may not be different from the disclosure in this announcement. Shareholders and potential investors are advised to read carefully the results announcement of the Group for the Year 2025 which is expected to be published in late March 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 10 March 2026

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the website of the Stock Exchange at www.hkex.com.hk for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

* *For identification purpose only*